Catalyst

Slingshot members are tracking this event:

Merck (MRK) Announces Phase 3 KEYNOTE-045 Results Evaluating Keytruda in Advanced Urothelial Cancer

Source Link:
http://www.mercknewsroom.com/news-release/oncology-newsroom/mercks-keynote-045-studying-keytruda-pembrolizumab-advanced-bladder-c

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MRK
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Oct 21, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Keynote-045, Keytruda, Advanced Urothelial Cancer, Bladder Cancer
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.